Headlines about pSivida Corp. (NASDAQ:PSDV) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. pSivida Corp. earned a news impact score of 0.13 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.8297424438076 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news stories that may have effected Accern’s rankings:

Shares of pSivida Corp. (NASDAQ:PSDV) remained flat at $$1.33 during mid-day trading on Friday. The company had a trading volume of 272,117 shares, compared to its average volume of 760,212. pSivida Corp. has a 1-year low of $1.03 and a 1-year high of $2.45.

pSivida Corp. (NASDAQ:PSDV) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.15). The firm had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.74 million. pSivida Corp. had a negative return on equity of 139.56% and a negative net margin of 226.31%. equities analysts expect that pSivida Corp. will post -0.58 EPS for the current fiscal year.

PSDV has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of pSivida Corp. in a report on Wednesday, November 8th. Laidlaw initiated coverage on pSivida Corp. in a report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 target price for the company. Six research analysts have rated the stock with a buy rating, pSivida Corp. has an average rating of “Buy” and a consensus target price of $8.00.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/psivida-corp-psdv-earning-somewhat-favorable-media-coverage-report-shows/1726030.html.

About pSivida Corp.

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Insider Buying and Selling by Quarter for pSivida Corp. (NASDAQ:PSDV)

Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.